Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ RYBREVANT + LAZCLUZE — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Jazz Pharmaceuticals logo
JAZZRylaze/Enrylaze — Revenue from Contract with Customer, Excluding Assessed Tax
$103.7M+10.1%
Bristol-Myers Squibb logo
BMYBreyanzi — Total Revenues
$411M+56.3%
Pfizer logo
PFELorbrena — Revenues:
$305M+37.4%
Ligand Pharmaceuticals logo
LGNDRylaze — Total revenues and income
$3.22M+3.3%
Bristol-Myers Squibb logo
BMYReblozyl — Total Revenues
$555M+16.1%
Pfizer logo
PFEIbrance — Revenues:
$1.01B+3.2%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's rybrevant + lazcluze — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's RYBREVANT + LAZCLUZE — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported RYBREVANT + LAZCLUZE — sales to customers (note 9) of $257M in Q1 2026.
How has Johnson & Johnson's RYBREVANT + LAZCLUZE — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's RYBREVANT + LAZCLUZE — sales to customers (note 9) increased by 82.3% year-over-year, from $141M to $257M.
What is the long-term trend for Johnson & Johnson's RYBREVANT + LAZCLUZE — sales to customers (note 9)?
Over 2 years (2023 to 2025), Johnson & Johnson's RYBREVANT + LAZCLUZE — sales to customers (note 9) has grown at a 180.9% compound annual growth rate (CAGR), from $93M to $734M.
What does RYBREVANT + LAZCLUZE — sales to customers (note 9) mean?
This metric represents the total net revenue generated from the sale of specific oncology therapeutic products to external customers. It reflects the market adoption and commercial performance of these specialized pharmaceutical treatments within the company's broader portfolio. Tracking this revenue stream is essential for evaluating the growth trajectory of the firm's high-value oncology franchise.